Youtor
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=so-S0V3txuw
Predictors of response to olaparib: looking beyond BRCA. Inherited breast cancers can be caused by mutations in many genes involved in DNA repair beyond BRCA1 and 2. PARP inhibitors are effective in BRCA-related cancers because they specifically target cells defficient in DNA repair. A multi-center clinical trial is investigating how PARP inhibitor treatment can be used in breast cancers due to mutations in other DNA repair genes. Dr. Payal Shah, Assistant Professor of Medicine in the Division of Hematology-Oncology at Penn Medicine, explains one of the eight projects funded by the Penn Center for Precision Medicine’s Accelerator Funds 2017. • Learn more about the Penn Center for Precision Medicine: • http://pennmedicine.org/precision-med... • Learn how precision medicine is changing cancer care: • https://www.pennmedicine.org/cancer/a...
#############################
